a public good project by the
Synthesis
Company
of California

© 2026

Marc Thill | doi.page

0 works0 citations0 h-index

Marc Thill

University Medical Center Freiburg(DE)Agaplesion Markus Hospital(DE)

Publications by Year

Research Areas

Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Breast Implant and Reconstruction, Breast Lesions and Carcinomas

Most-Cited Works

→ Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study(2022)369 cited
→ Spatial predictors of immunotherapy response in triple-negative breast cancer(2023)286 cited
→ 20-Jahres-Ergebnisse einer 5‑jährigen Hormontherapie bei Mammakarzinom(2018)253 cited
→ The Central-European SentiMag study: Sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope(2014)195 cited
→ Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial(2024)190 cited
→ AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2016(2016)190 cited

→ Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer(2018)

164 cited

→ Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2 -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial(2018)153 cited

→ Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study(2021)151 cited

→ Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study(2020)134 cited